Gemcitabine

Catalog No.S1714 Synonyms: LY-188011, NSC 613327

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 67 Publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NEXmWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjTfJBZUUN3ME2wMlAxODR3ODDuUS=> NFr4fodUSU6JRWK=
ES4 M3fy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1mxXWlEPTB;MD6wNFA3PTNibl2= MlT1V2FPT0WU
ACHN NITB[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PXPWlEPTB;MD6wNFA5QDdibl2= M3\qfHNCVkeHUh?=
KYSE-510 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF60eldKSzVyPUCuNFAxQTd3IH7N M4D0dHNCVkeHUh?=
EW-7 NFLONGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMECyOVghdk1? M2rkO3NCVkeHUh?=
BFTC-905 NVnSUXNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjXPFFKSzVyPUCuNFA2OTVibl2= Mo\UV2FPT0WU
KE-37 M4K5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3iz[WlEPTB;MD6wNFU3OSCwTR?= NGHEOFFUSU6JRWK=
SBC-5 NYrR[5c2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HjUGlEPTB;MD6wNFU4KG6P NYLmS2dHW0GQR1XS
NKM-1 NH\oc3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH4SZlKSzVyPUCuNFA4ODlibl2= Mkm0V2FPT0WU
RH-1 NGm3UWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMEC3NVghdk1? M{PrXHNCVkeHUh?=
ALL-PO MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHK5OHpKSzVyPUCuNFA5OyCwTR?= MmrZV2FPT0WU
QIMR-WIL NG\o[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;DUWlEPTB;MD6wNFg6PCCwTR?= NHXnfYZUSU6JRWK=
A375 NWr2S21wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4WwVGlEPTB;MD6wNFk6PSCwTR?= M3j5N3NCVkeHUh?=
SIG-M5 M3jaSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnr5TWM2OD1yLkCxNFQhdk1? Ml;uV2FPT0WU
KGN MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TyOmlEPTB;MD6wNVA5KG6P NWPWVXlLW0GQR1XS
EW-13 NULJcZQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMEGxNkBvVQ>? M4[wbHNCVkeHUh?=
NCI-SNU-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrDSYFzUUN3ME2wMlAyPiCwTR?= MkDDV2FPT0WU
PSN1 M3LwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnNSXF7UUN3ME2wMlAyPjVibl2= MV;TRW5ITVJ?
HUTU-80 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwMEG2OkBvVQ>? M3rXT3NCVkeHUh?=
EW-16 NH\yRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIixcmNKSzVyPUCuNFI{KG6P NVvRNXZZW0GQR1XS
786-0 MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHnb5FKSzVyPUCuNFI{KG6P MVHTRW5ITVJ?
ES1 M3joXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXmNVFXUUN3ME2wMlAzPjhibl2= Ml23V2FPT0WU
RKO MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1SzWWlEPTB;MD6wNlc6KG6P M3[2[3NCVkeHUh?=
ESS-1 NXPoPIFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jxe2lEPTB;MD6wNlg3KG6P M2[0U3NCVkeHUh?=
SK-UT-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVO2RlJ[UUN3ME2wMlAzQTdibl2= NFjwVXRUSU6JRWK=
LB2241-RCC NHK0bIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfNUXJDUUN3ME2wMlA{OThibl2= NEj1fJZUSU6JRWK=
CHL-1 NUXk[2tqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHZOmtKSzVyPUCuNFMzPCCwTR?= NYPMZ5RGW0GQR1XS
SW1783 MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vKR2lEPTB;MD6wN|M3KG6P M13OeHNCVkeHUh?=
MEL-JUSO MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwMEO5NUBvVQ>? MYnTRW5ITVJ?
HT-29 M3nPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHVUnk3UUN3ME2wMlA1OTNibl2= NITEPG5USU6JRWK=
SNG-M NF:5XZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;4ZZRKSzVyPUCuNFQzPSCwTR?= MUjTRW5ITVJ?
TE-15 MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HnbmlEPTB;MD6wOFY1KG6P NYLVPHVsW0GQR1XS
HOS M2rtfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fmXGlEPTB;MD6wOFghdk1? M2DDe3NCVkeHUh?=
BB65-RCC M4DP[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDv[2xKSzVyPUCuNFUyOiCwTR?= MV7TRW5ITVJ?
HCE-4 M3PHZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwMEWyPEBvVQ>? MkTjV2FPT0WU
MHH-ES-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMEWzNUBvVQ>? NX3PTI9NW0GQR1XS
RPMI-7951 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LKc2lEPTB;MD6wOVQyKG6P NYjHV4ljW0GQR1XS
IST-SL2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjSPFBUUUN3ME2wMlA2QDRibl2= NUXROm9ZW0GQR1XS
CMK MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLVW4VPUUN3ME2wMlA2QDZibl2= MUPTRW5ITVJ?
GR-ST NFPKbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L0N2lEPTB;MD6wOVk2KG6P NHzadXVUSU6JRWK=
NALM-6 NF\DUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\Jc2FKSzVyPUCuNFYzOiCwTR?= MmTaV2FPT0WU
RPMI-6666 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;peJlVUUN3ME2wMlA3PTJibl2= MXXTRW5ITVJ?
LC-2-ad NFPGRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwME[1N{BvVQ>? NVrsUXc6W0GQR1XS
ARH-77 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:4NmlEPTB;MD6wO|EyKG6P NWLxcmtzW0GQR1XS
IST-MEL1 NWLhSIU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\aNpBKSzVyPUCuNFczPiCwTR?= NFnrNoJUSU6JRWK=
SW1710 M1zleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMEe1NUBvVQ>? MVHTRW5ITVJ?
DEL MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrVZYpKSzVyPUCuNFg5PyCwTR?= NET4W21USU6JRWK=
AGS M1nzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMEmwNkBvVQ>? M1ruPXNCVkeHUh?=
NCI-H2122 NEPaTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnHdndKSzVyPUCuNFk1PiCwTR?= NGnHRWVUSU6JRWK=
HSC-4 NHz6eW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXvU41kUUN3ME2wMlExOiCwTR?= MYrTRW5ITVJ?
AM-38 Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXEcoFKSzVyPUCuNVIyKG6P M2SwXnNCVkeHUh?=
769-P MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLlOGJKSzVyPUCuNVI{KG6P NUTLeI1SW0GQR1XS
RT-112 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMUK3JI5O Ml7RV2FPT0WU
MCF7 NV\hbYVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17TbmlEPTB;MD6xN|Yhdk1? MWrTRW5ITVJ?
IGROV-1 MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrjUG5sUUN3ME2wMlE1PSCwTR?= NIrlVmxUSU6JRWK=
OCI-AML2 MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMUS3JI5O NIqySFdUSU6JRWK=
NCI-H1299 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTwOHBHUUN3ME2wMlE2PyCwTR?= MX\TRW5ITVJ?
A431 NFHLSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfve4VKSzVyPUCuNVg{KG6P M{X0[3NCVkeHUh?=
SW982 NHfoU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PMWmlEPTB;MD6yNVMhdk1? MlnmV2FPT0WU
BB30-HNC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\LeWlEPTB;MD6yN|Ehdk1? Ml3BV2FPT0WU
ACN MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LER2lEPTB;MD6yOFQhdk1? MVXTRW5ITVJ?
647-V M1K4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXHWpNKSzVyPUCuNlQ5KG6P NETQXVBUSU6JRWK=
SK-PN-DW NHWzZ|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjXflIzUUN3ME2wMlI3PiCwTR?= M2PzRXNCVkeHUh?=
LCLC-97TM1 M2nhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfrOoRKSzVyPUCuNlY4KG6P MoXKV2FPT0WU
LB1047-RCC MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMk[5JI5O MnHiV2FPT0WU
A2780 M3PIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn6TphKSzVyPUCuNlchdk1? MV\TRW5ITVJ?
C-33-A NIPlRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7qcpdtUUN3ME2wMlI4OyCwTR?= MUXTRW5ITVJ?
NCI-H2228 NEW5OpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;3UolKSzVyPUCuN|E1KG6P M3jqOHNCVkeHUh?=
TE-5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmqyTWM2OD1yLkOxOkBvVQ>? MoP2V2FPT0WU
HC-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwM{K3JI5O MnPBV2FPT0WU
SK-MES-1 MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3zTWM2OD1yLkOyPEBvVQ>? MVXTRW5ITVJ?
NCI-H1355 NYXDfnY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWey[2pwUUN3ME2wMlM5OSCwTR?= NUn3PZFrW0GQR1XS
YKG-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3WTWM2OD1yLkSxPUBvVQ>? MUTTRW5ITVJ?
RS4-11 NYiwSmtST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELSTmVKSzVyPUCuOFM{KG6P MlXqV2FPT0WU
Daoy M2PsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLhdZIzUUN3ME2wMlQ2PiCwTR?= M1;zWXNCVkeHUh?=
A3-KAW M2DIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHvdGR3UUN3ME2wMlU2OSCwTR?= NG\ydnlUSU6JRWK=
SK-MEL-30 NGTNPWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWq0RWNnUUN3ME2wMlU2PCCwTR?= MlrKV2FPT0WU
U031 M32x[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmixTWM2OD1yLkW2OUBvVQ>? MlTZV2FPT0WU
SK-LMS-1 M3XITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLCTWM2OD1yLkW3PEBvVQ>? MXzTRW5ITVJ?
ES6 MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XO[mlEPTB;MD61PFYhdk1? MYfTRW5ITVJ?
EoL-1-cell NFzHUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwNkG2JI5O MnfmV2FPT0WU
NCI-H2009 NHTabIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPSXnJKSzVyPUCuOlE6KG6P MXXTRW5ITVJ?
A4-Fuk M4S1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml36TWM2OD1yLk[yOkBvVQ>? M1;id3NCVkeHUh?=
KYSE-270 MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwNkO0JI5O NWjRTIlrW0GQR1XS
SK-LU-1 MlP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfwV2NRUUN3ME2wMlY2PSCwTR?= MmHXV2FPT0WU
SW872 MlvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEO3O3hKSzVyPUCuO|Y2KG6P M17HPXNCVkeHUh?=
ES8 MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T3bWlEPTB;MD63PEBvVQ>? NXvJVFRMW0GQR1XS
G-402 M3vaemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkT6TWM2OD1yLke4OEBvVQ>? MnrBV2FPT0WU
ATN-1 NWTlSGo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXu2ZY5mUUN3ME2wMlgxPyCwTR?= Moj2V2FPT0WU
DoTc2-4510 MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXNWJNwUUN3ME2wMlkxOSCwTR?= M1\ET3NCVkeHUh?=
MES-SA NEizXWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWq2ZpB2UUN3ME2wMlkxPSCwTR?= NFXUeHlUSU6JRWK=
SF268 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwOUK3JI5O NVrJR5d3W0GQR1XS
SF539 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorsTWM2OD1zLkCyJI5O NGnZSGpUSU6JRWK=
NB69 NIDKVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PTTmlEPTB;MT6wOUBvVQ>? M2Dq[3NCVkeHUh?=
8505C NUnWPFhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\ueIhCUUN3ME2xMlA3KG6P NI\USVBUSU6JRWK=
CAL-12T NH\4PIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFwMEigcm0> M4fiVnNCVkeHUh?=
BHY NYrsPWJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFwMUSgcm0> MUfTRW5ITVJ?
LB647-SCLC NHfEUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HDTGlEPTB;MT6xPEBvVQ>? MVrTRW5ITVJ?
CAL-62 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXQdI9kUUN3ME2xMlIzKG6P NILncWNUSU6JRWK=
MEG-01 NVvDOG1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFwMkegcm0> MknoV2FPT0WU
MG-63 NXvnd5g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nZbGlEPTB;MT6zN{BvVQ>? M1m1V3NCVkeHUh?=
SW620 M2K3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq0ZmRKSzVyPUGuN|Uhdk1? MnjIV2FPT0WU
A388 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwM{[gcm0> NULK[ZVMW0GQR1XS
BCPAP M{DNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DhRWlEPTB;MT60OUBvVQ>? MYPTRW5ITVJ?
P30-OHK NXKwc5l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFwNE[gcm0> NYrJeWVlW0GQR1XS
Ca9-22 Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH65e|BKSzVyPUGuOVQhdk1? NYO3XmRuW0GQR1XS
VMRC-RCZ NFTRO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n6RWlEPTB;MT61OEBvVQ>? MVzTRW5ITVJ?
LOXIMVI M3vaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrnTWM2OD1zLk[gcm0> NXPQXHBpW0GQR1XS
L-540 MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r3NGlEPTB;MT62JI5O M3;wV3NCVkeHUh?=
NTERA-S-cl-D1 MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLyeHo{UUN3ME2xMlY1KG6P M1LqSnNCVkeHUh?=
MFH-ino NHzWXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH0cWJKSzVyPUGuOlYhdk1? NXm0TFM3W0GQR1XS
Calu-6 M3PM[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rkSGlEPTB;MT63N{BvVQ>? MWTTRW5ITVJ?
HEL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHYTWM2OD1zLke5JI5O MUTTRW5ITVJ?
CAL-33 NHzTeJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknhTWM2OD1zLki5JI5O MUPTRW5ITVJ?
HSC-3 NX3OTHZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFwOUGgcm0> MYDTRW5ITVJ?
KU812 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33TR2lEPTB;MT65NUBvVQ>? M3jWV3NCVkeHUh?=
EB2 Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnoNJV7UUN3ME2yMlAyKG6P MnjvV2FPT0WU
SR M4G3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3uTWM2OD1{LkGyJI5O M1\TUnNCVkeHUh?=
NCI-H2087 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPQSpdKSzVyPUKuNVQhdk1? NGPUWZRUSU6JRWK=
H4 NF\5fFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDiXZdlUUN3ME2yMlE5KG6P NHi3ZlRUSU6JRWK=
EW-1 NHnCSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1GzeGlEPTB;Mj6yNkBvVQ>? MULTRW5ITVJ?
MC-IXC M33TRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzEUJp1UUN3ME2yMlI3KG6P NYfsVWZuW0GQR1XS
NCI-H727 M3jzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfhTWM2OD1{LkWxJI5O NWW1UnpkW0GQR1XS
MRK-nu-1 NFfQbmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPRTWM2OD1{LkW3JI5O MVTTRW5ITVJ?
COLO-668 M{flVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjyTWM2OD1{Lk[2JI5O NUPlXY9tW0GQR1XS
CGTH-W-1 NW[5TY5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLmTWM2OD1{LkeyJI5O MW\TRW5ITVJ?
CHP-212 NV\GT21oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfuXGFHUUN3ME2yMlc2KG6P M3XiVXNCVkeHUh?=
GI-1 M2HGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HweWlEPTB;Mj63OkBvVQ>? MkXiV2FPT0WU
HCC1806 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXTTWM2OD1{LkmxJI5O M3r5cXNCVkeHUh?=
HLE NUT0dHVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zLPGlEPTB;MzDuUS=> MnPvV2FPT0WU
HSC-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHKTWM2OD1|LkCzJI5O NHvCRWdUSU6JRWK=
DMS-273 NUSwXG9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLETWM2OD1|LkC3JI5O MlnRV2FPT0WU
DU-4475 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzGTWM2OD1|LkG0JI5O NF3VN|hUSU6JRWK=
LXF-289 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFviSZdKSzVyPUOuN|Ehdk1? MWXTRW5ITVJ?
PANC-03-27 MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTNwNUGgcm0> Ml3CV2FPT0WU
GAMG MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTNwN{Sgcm0> NXWyfGd6W0GQR1XS
NCI-H522 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS4UmVEUUN3ME20MlM1KG6P M3qzdXNCVkeHUh?=
SW626 M3jTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7tTWM2OD12LkS2JI5O MVLTRW5ITVJ?
HT-144 NHnl[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHXTWM2OD12LkmyJI5O MnnjV2FPT0WU
MEL-HO MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rlRWlEPTB;NT6xOkBvVQ>? M3zORXNCVkeHUh?=
BE-13 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLuTWM2OD13LkKxJI5O MUfTRW5ITVJ?
VA-ES-BJ Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXYXY9mUUN3ME21MlI3KG6P MnPtV2FPT0WU
NCI-H441 NI\jR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\6UphwUUN3ME21MlYhdk1? Mmr1V2FPT0WU
KP-4 MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoK2TWM2OD13Lk[xJI5O MYjTRW5ITVJ?
LoVo Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLJTWM2OD13LkexJI5O M3L1bnNCVkeHUh?=
HT-1080 NV7te|dXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXVTWM2OD13LkizJI5O NXf5VlkxW0GQR1XS
GB-1 M{fGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TuOGlEPTB;NT64OEBvVQ>? NXvZfXE{W0GQR1XS
IA-LM NE[xR3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO3TWM2OD13LkmxJI5O NV\Ld2JWW0GQR1XS
8-MG-BA NFyxUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnj2TWM2OD13LkmzJI5O Mlq4V2FPT0WU
SK-HEP-1 M3vsdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXZWlhHUUN3ME22MlE1KG6P MonBV2FPT0WU
697 M3LGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nrS2lEPTB;Nj6yOUBvVQ>? M37kT3NCVkeHUh?=
KYSE-450 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\CTWM2OD14LkOyJI5O MmG2V2FPT0WU
HCC2998 NWW1WpdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTZwM{Sgcm0> MVLTRW5ITVJ?
HD-MY-Z NYPSToZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTZwNkigcm0> M2exR3NCVkeHUh?=
OS-RC-2 NGG2VHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfJW21UUUN3ME22MlY5KG6P MmjNV2FPT0WU
SF126 M4DBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS2Zow1UUN3ME23MlA2KG6P M{X3U3NCVkeHUh?=
Ca-Ski MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTdwMEmgcm0> NF3EXZlUSU6JRWK=
NCI-H358 NHr3TodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PYcGlEPTB;Nz6xOkBvVQ>? M1vPPXNCVkeHUh?=
J82 NWC2RmdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz5TWM2OD15LkSxJI5O MonUV2FPT0WU
NCI-H2342 M{\ob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{CxcGlEPTB;Nz62N{BvVQ>? M{WyV3NCVkeHUh?=
OVCAR-8 NWHGR2RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHZ[2ZKSzVyPUeuPUBvVQ>? MUTTRW5ITVJ?
TE-8 NYnVWHZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLPTWM2OD16IH7N MlfkV2FPT0WU
ETK-1 MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRThwMEigcm0> NXLQbmFlW0GQR1XS
HAL-01 MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;LS5JDUUN3ME24MlIhdk1? Ml30V2FPT0WU
KYSE-150 M3TEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\V[Zp6UUN3ME24MlQ4KG6P NHjZW|NUSU6JRWK=
NCI-H810 NEL6WXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHFTWM2OD16LkW2JI5O MkK2V2FPT0WU
ONS-76 M4DzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRThwNkigcm0> M3;aNnNCVkeHUh?=
NMC-G1 NWT6PJhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXMTWM2OD16Lke2JI5O M2DPeHNCVkeHUh?=
C3A MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHTcHRKSzVyPUiuPFQhdk1? NH;GOGZUSU6JRWK=
PA-1 NFfCTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;BTWM2OD16Lkm5JI5O MkDsV2FPT0WU
SH-4 M3vPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlewTWM2OD17LkCyJI5O MnPXV2FPT0WU
EFO-27 NGXBNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTlwMEWgcm0> Ml;DV2FPT0WU
CAPAN-1 M3ftSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;FfXdKSzVyPUmuNlMhdk1? MWDTRW5ITVJ?
DU-145 MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVS3UXZxUUN3ME25MlI6KG6P MWjTRW5ITVJ?
A101D M3PCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3Wblh{UUN3ME25MlM4KG6P NIe4O3dUSU6JRWK=
ST486 M3PHfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7yTWM2OD17LkSxJI5O M2PSNXNCVkeHUh?=
NCI-H1437 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3uycmlEPTB;OT60NkBvVQ>? NIPXWmhUSU6JRWK=
HGC-27 M2DTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTlwNjDuUS=> Mm[4V2FPT0WU
8305C NI\wdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PiUGlEPTB;OT62OEBvVQ>? M17u[HNCVkeHUh?=
OCUB-M NEO2WmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDHTWM2OD1zMD6wN{BvVQ>? NGD0OIFUSU6JRWK=
COLO-679 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXx[49KSzVyPUGwMlA4KG6P MX\TRW5ITVJ?
Detroit562 NFjq[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrnNHJyUUN3ME2xNE41OiCwTR?= MoO5V2FPT0WU
A204 MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDDTWM2OD1zMT6xOkBvVQ>? NY[2[4JkW0GQR1XS
NCI-H1734 NGrCT|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{KzVmlEPTB;MUGuNlkhdk1? MXXTRW5ITVJ?
MC-CAR MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnKdGtKSzVyPUGxMlU5KG6P NUWwRmZJW0GQR1XS
NCI-H2170 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFzLkm3JI5O MoDtV2FPT0WU
NCI-SNU-5 NITQT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jiemlEPTB;MUKuNVMhdk1? NEjIZmdUSU6JRWK=
HCE-T MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\RTWM2OD1zMj60NkBvVQ>? NXKzdXp2W0GQR1XS
KYSE-180 NHXwVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TXSGlEPTB;MUKuPFEhdk1? M3\HeHNCVkeHUh?=
C8166 NX7WOGg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfrTWM2OD1zMz6wPEBvVQ>? M4r0b3NCVkeHUh?=
NCI-H460 M33ZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDTZpBKSzVyPUGzMlU1KG6P NXPCe|l6W0GQR1XS
SNU-449 MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XWd2lEPTB;MUOuO|chdk1? Mn;OV2FPT0WU
MDA-MB-468 MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTF2LkGyJI5O MlfVV2FPT0WU
COR-L23 MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\qdmlEPTB;MUSuNVMhdk1? NWDCXGVMW0GQR1XS
CTV-1 MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfpbnlKSzVyPUG0MlE1KG6P M1j4OnNCVkeHUh?=
BL-41 NFnBcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjLO5hWUUN3ME2xOE4{PyCwTR?= MnL5V2FPT0WU
IGR-1 NF\aXI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrVTWM2OD1zND60NkBvVQ>? MXLTRW5ITVJ?
TK10 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTVPWg{UUN3ME2xOE41QSCwTR?= MnHaV2FPT0WU
REH NHPKeGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV65fnd4UUN3ME2xOE42OSCwTR?= NXruUpZCW0GQR1XS
LU-139 NY\WWWJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF2LkW5JI5O NHfMVHZUSU6JRWK=
KP-N-YS NXrUU5J4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ruR2lEPTB;MUSuPVchdk1? NWfqTnVCW0GQR1XS
PANC-10-05 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\FOmlEPTB;MUWuN|ghdk1? MnvvV2FPT0WU
HL-60 NH;UN5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLuTWM2OD1zNT62PUBvVQ>? NUTXWIY{W0GQR1XS
T84 M4KzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF3Lkm2JI5O MmLGV2FPT0WU
RPMI-8226 NWn1UJR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTF4LkCyJI5O NILlNlNUSU6JRWK=
UM-UC-3 MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrMcmRKSzVyPUG2MlE3KG6P NG\wXG1USU6JRWK=
TE-10 NWPtdYtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[2VXZKSzVyPUG2MlIyKG6P NGGwcoxUSU6JRWK=
CAL-148 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jVemlEPTB;MUeuNlMhdk1? NXzpUlZoW0GQR1XS
BV-173 Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;3SldKSzVyPUG3MlI4KG6P NYeybpVqW0GQR1XS
Calu-3 MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHYTWM2OD1zNz6yPUBvVQ>? MWHTRW5ITVJ?
RPMI-2650 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHkTWM2OD1zNz61PUBvVQ>? NVntXpd6W0GQR1XS
MKN45 M3PkW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfoUpBVUUN3ME2xO{44OyCwTR?= NEDSNFBUSU6JRWK=
NUGC-3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PLT2lEPTB;MUiuN|Qhdk1? MlHKV2FPT0WU
NCI-H520 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTlPIlGUUN3ME2xPE44PyCwTR?= MnmyV2FPT0WU
CCRF-CEM M3;VcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NISyZ4hKSzVyPUG4Mlg2KG6P M2DiUnNCVkeHUh?=
NCI-H2405 NF31cZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;pTWM2OD1zOT6xJI5O M{n0cnNCVkeHUh?=
ES7 NIGxcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDEcFBKSzVyPUG5Mlc3KG6P NV3w[ZhSW0GQR1XS
BPH-1 M4jhemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUSwXJdnUUN3ME2yNE4zQCCwTR?= M{TofXNCVkeHUh?=
SAS M17wXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;xWnlKSzVyPUKwMlUhdk1? Mn\xV2FPT0WU
HuCCT1 M32xZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnZN2NKSzVyPUKwMlU5KG6P Mo\pV2FPT0WU
LOUCY MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITVWopKSzVyPUKwMlY3KG6P MlTzV2FPT0WU
NCI-H292 NVS3bmhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1r6O2lEPTB;MkCuO|khdk1? NGnOdZlUSU6JRWK=
G-361 M2HRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGWyZYVKSzVyPUKxMlA4KG6P M1exUXNCVkeHUh?=
M059J M3PkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjtSpNKSzVyPUKxMlA5KG6P NYHHe3hpW0GQR1XS
NCI-H1651 NVrqS4xET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJzLkGxJI5O M4fhVXNCVkeHUh?=
KALS-1 MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\mUYxKSzVyPUKxMlM6KG6P MWLTRW5ITVJ?
DJM-1 NXHDd5NNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\NeXBNUUN3ME2yNU42QSCwTR?= MWjTRW5ITVJ?
AU565 MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJzLkizJI5O M1jETHNCVkeHUh?=
HCC38 NFS5RmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jWTmlEPTB;MkGuPVUhdk1? NFPlXYRUSU6JRWK=
U251 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJ{LkK3JI5O NFLG[5BUSU6JRWK=
ABC-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXSVJlSUUN3ME2yNk43PSCwTR?= Mn\mV2FPT0WU
SK-NEP-1 NWnCN2dIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV25[G8xUUN3ME2yNk46OyCwTR?= MVLTRW5ITVJ?
CESS M3XLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nqSmlEPTB;MkOuNVkhdk1? M33id3NCVkeHUh?=
MIA-PaCa-2 MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJ|LkO2JI5O MknuV2FPT0WU
SUP-T1 MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj6SXFKSzVyPUKzMlQ4KG6P M2PZ[3NCVkeHUh?=
L-428 MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrYfnZ7UUN3ME2yN{43OiCwTR?= MmH6V2FPT0WU
SW954 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17hXGlEPTB;MkOuOlghdk1? NXvkPVNjW0GQR1XS
HO-1-N-1 NGnPd|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTJ|Lke3JI5O MX;TRW5ITVJ?
CHP-126 NEPDc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILx[G9KSzVyPUK0MlE1KG6P MVfTRW5ITVJ?
HMV-II M1fZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJ2LkO0JI5O NYLxTGJFW0GQR1XS
NB10 MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XRRWlEPTB;MkSuN|chdk1? NGPabXRUSU6JRWK=
A172 M3TzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkO0TWM2OD1{ND63NUBvVQ>? MYrTRW5ITVJ?
MONO-MAC-6 NEfZbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK0[HZ{UUN3ME2yOE45PCCwTR?= M1LjcXNCVkeHUh?=
NCI-H1650 MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLFO25KSzVyPUK1MlQhdk1? NVzFcGsxW0GQR1XS
NH-12 M1LIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7lOnhKSzVyPUK1MlUhdk1? MUTTRW5ITVJ?
ML-2 NX;FNGp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJ3Lke0JI5O MknHV2FPT0WU
MZ2-MEL MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTJ4LkKyJI5O MUDTRW5ITVJ?
COLO-684 M4TJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rQd2lEPTB;Mk[uOFEhdk1? M13tUnNCVkeHUh?=
HuP-T4 M1\DVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fG[mlEPTB;MkeuN{BvVQ>? NHPnRY9USU6JRWK=
SW837 MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJ5Lk[yJI5O MXzTRW5ITVJ?
MDA-MB-231 NWCxd2hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvud5lOUUN3ME2yO{44QCCwTR?= NXX1ZXU6W0GQR1XS
KYSE-140 NXG1WVkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PGeGlEPTB;MkeuPVEhdk1? MnXtV2FPT0WU
NOMO-1 MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vVRmlEPTB;MkiuOlghdk1? NFrRSoVUSU6JRWK=
GP5d NHvmTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\mSG5KSzVyPUK4MlczKG6P NY\ZR20xW0GQR1XS
COR-L105 NYnnU49LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnkTWM2OD1{OT60NkBvVQ>? MXvTRW5ITVJ?
LS-411N M363Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnvTWM2OD1{OT64PEBvVQ>? MVTTRW5ITVJ?
NY NHP3W|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTNyLkG4JI5O M362THNCVkeHUh?=
NCI-H2030 NEKxUJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTNyLkS1JI5O MWDTRW5ITVJ?
CCF-STTG1 NF3iVpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLGTWM2OD1|MT60NkBvVQ>? NWjGcGtZW0GQR1XS
NCI-H1703 MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzDcZJKSzVyPUOxMlc5KG6P Mn\UV2FPT0WU
TUR NWTDe4NlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTN{LkCzJI5O M1fuTnNCVkeHUh?=
NOS-1 NW\FNph6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTN{LkS0JI5O NUPqbY1FW0GQR1XS
A2058 NFPJNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjWW|RKSzVyPUOyMlg{KG6P NWGwOZNkW0GQR1XS
LCLC-103H MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PoV2lEPTB;M{OuNlUhdk1? MX3TRW5ITVJ?
NCI-H510A Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HscmlEPTB;M{OuNlchdk1? M33ZR3NCVkeHUh?=
BC-1 M1i1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfVboFKSzVyPUOzMlc4KG6P NUX5Z4s6W0GQR1XS
SK-CO-1 NYXJO2t7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe0TndKSzVyPUO0MlAyKG6P M4HW[nNCVkeHUh?=
A673 M2j2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPuSWFKSzVyPUO0MlE4KG6P NXPZSIRMW0GQR1XS
VM-CUB-1 NXfMU4pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Gz[WlEPTB;M{SuOlkhdk1? MnTsV2FPT0WU
HH M3XofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTN3LkC2JI5O MXXTRW5ITVJ?
CAL-27 MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvhPYVKSzVyPUO1MlE3KG6P NESwSIhUSU6JRWK=
NEC8 MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3WW3c2UUN3ME2zOU4{PyCwTR?= M3;henNCVkeHUh?=
BxPC-3 NE\YW|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELDXWhKSzVyPUO2MlkyKG6P MmKwV2FPT0WU
SNB75 MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULLUoFGUUN3ME2zO{4zPCCwTR?= NXHHTYpJW0GQR1XS
NB13 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDhOGlKSzVyPUO4MlI{KG6P NGrLXWpUSU6JRWK=
SK-OV-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPETWM2OD1|OD63OEBvVQ>? M{iyOHNCVkeHUh?=
ME-180 MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDXc45KSzVyPUO4Mlghdk1? M4jMNXNCVkeHUh?=
JiyoyeP-2003 M132WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH25bJpKSzVyPUO5MlM5KG6P M3LLZ3NCVkeHUh?=
LU-134-A MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TM[GlEPTB;NECuNFIhdk1? MoG5V2FPT0WU
LS-123 NIeyVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3xfpU2UUN3ME20NE4zQCCwTR?= NIDyXI9USU6JRWK=
COLO-800 NGGzVHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTTXWRuUUN3ME20NE42PiCwTR?= NXfXZ4x6W0GQR1XS
LB831-BLC Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWW0[It4UUN3ME20NU45PSCwTR?= MWLTRW5ITVJ?
NCI-H747 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj3e4ZKSzVyPUSyMlI5KG6P NEDKfVRUSU6JRWK=
MZ7-mel M164fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7mc4xHUUN3ME20Nk43PiCwTR?= NFi5UphUSU6JRWK=
GT3TKB MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLafZBKSzVyPUSyMlczKG6P MYLTRW5ITVJ?
MOLT-16 M2\oOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTR|LkC1JI5O NF7LelZUSU6JRWK=
23132-87 NH\lc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTR|LkC1JI5O NX7RbVlUW0GQR1XS
PF-382 NYfNV|JMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn0VG56UUN3ME20OE4zOiCwTR?= NVLtUFVmW0GQR1XS
ES3 MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO1fJp4UUN3ME20OE43KG6P NHPHW|VUSU6JRWK=
SW756 NY\VZYFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rsWGlEPTB;NEWuNVQhdk1? NVjrXlFlW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p70S6K1 / p-S6 / HIF-1α ; 

PubMed: 27765914     


Cells were treated with different doses of gemcitabine (0, 1.5 and 2.5 μM), the expression levels of p70S6K1, p-S6 and HIF-1α were determined by Western blotting. GAPDH is used as an internal control.

PARP / Cleaved PARP / Cleaved caspase-3 / phopho-p38 / p38 / p-JNK / JNK / p-c-Jun; 

PubMed: 24409315     


AsPC-1, BxPC-3, and COLO-357 cells were incubated for the indicated times with 100 ng/ml, 10 ng/ml, and 5 ng/ml gemcitabine, respectively, and analyzed by immunoblotting. 

27765914 24409315
Immunofluorescence
Bim1; 

PubMed: 27177084     


Gemcitabine enhanced nuclear accumulation of Bmi1 by immunofluorescence staining. The graphs shown are representative results of three independently repeated experiments. Scale bar, 50 μm.

27177084
Growth inhibition assay
Cell viability; 

PubMed: 27765914     


A and B. Pancreatic adenocarcinoma cells Bxpc-3 (A) and Panc-1 (B) were treated with gemcitabine (GEM) for 48 h at different doses. The cell viability was analyzed by CCK-8 assay, and normalized to cells without gemcitabine treatment. 

27765914
In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Protocol

Solubility (25°C)

In vitro DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water (warmed)
For best results, use promptly after mixing.
52mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
in solvent
Synonyms LY-188011, NSC 613327

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04051047 Not yet recruiting Drug: Gemcitabine|Procedure: Tumor biopsy and blood draw Glial Tumor of Brain|Diffuse Intrinsic Pontine Glioma|Glioma University of Michigan Rogel Cancer Center|University of Colorado Denver November 30 2019 Early Phase 1
NCT03669601 Not yet recruiting Drug: AZD6738|Drug: Gemcitabine Cancer CCTU- Cancer Theme|AstraZeneca|Cambridge University Hospitals NHS Foundation Trust September 30 2019 Phase 1
NCT04046887 Not yet recruiting Drug: Lonsurf|Drug: Gemcitabine|Drug: Nab-Paclitaxel Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma Patrick Joseph Loehrer Sr.|Indiana University|Taiho Oncology Inc. August 2019 Phase 1
NCT03865563 Not yet recruiting Drug: Retrograde venous infusion of gemcitabine/lipiodol Pancreatic Adenocarcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins July 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • Answer:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID